APR 11, 2017 8:00 AM PDT

WEBINAR: Enhancing Checkpoint Blockade in Lymphoma with In Situ Vaccination

Sponsored by: Fluidigm
Speakers

Abstract

DATE: April 11, 2017
TIME: 8:00 AM PT, 11:00 AM ET

 

Checkpoint blockade therapy for cancer has had tremendous impact on clinical outcomes, yet only a subset of patients respond. Recent studies show that response to checkpoint blockade does not always correlate with tumor-associated antigen (TAA) load and so must be determined by factors beyond mutational burden. This suggests that checkpoint blockade is limited by suboptimal cross-presentation of TAA by activated dendritic cells (DC) and will be potentiated by recruitment, loading and activation of cross-presenting DC at the tumor site.

 

To test this hypothesis, an early-phase trial (NCT01976585) in low-grade lymphoma was carried out testing a unique in situ vaccine (ISV) combining: 1) fms-like tyrosine kinase 3 ligand (FLT3L) to recruit DC, 2) radiotherapy to load FLT3L-mobilized DC with TAA, and 3) toll-like receptor agonist (TLRa) to activate TAA-loaded DC for cross-presentation. Strikingly, Brody and colleagues found partial and complete systemic tumor regressions at distant, untreated tumors. They also found specific elimination of malignant B cells with sparing of healthy B cells, suggesting a systemic anti-tumor immune response.

 

This data prompted a new trial in which anti-PD1 monoclonal antibody (mAb) and ISV (used to increase efficacy) are combined with a novel immune-monitoring approach involving co-administration of "surrogate antigens (Ag)" at the ISV site. The approach is being applied to multiple cancer types, including breast, head and neck, melanoma and sarcoma.

 

In this webinar, Brody will discuss these studies, including the key role mass cytometry played in defining the effects of treatment on the intratumoral and systemic immune repertoire with high resolution and in profiling the distinct checkpoint/co-activator molecules on TAA-specific, surrogate-Ag-specific and bulk CD8 T cells.

 

Michelle Poulin, PhD, from Fluidigm will present a brief overview of mass cytometry, describing the basic principles and workflow of the technology, including recent advancements.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
JUL 15, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
JUL 15, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: July 15, 2021 Time: 9:00am (PDT), 12:00pm (EDT) The Pisces workflow robust, easy-to-use, end-to-end multi-omics solution for highly multiplexed targeted Spatial RNA analysis. VeranomeB...
APR 11, 2017 8:00 AM PDT

WEBINAR: Enhancing Checkpoint Blockade in Lymphoma with In Situ Vaccination

Sponsored by: Fluidigm

Specialty

Cancer Research

Immunology

Cancer Therapeutics

Biotechnology

Molecular Biology

Cell Biology

Cancer Diagnostics

Oncology

Biomarkers

Genetics

Clinical Research

Clinical Diagnostics

Biochemistry

Infectious Disease

Molecular Diagnostics

Geography

North America63%

Europe15%

Asia13%

Africa3%

South America2%

Oceania1%

Registration Source

Website Visitors100%

Job Title

Student15%

Research Scientist13%

Scientist13%

Executive11%

Educator/Faculty10%

Facility/Department Manager10%

Medical Laboratory Technician6%

Post Doc6%

Medical Doctor/Specialist6%

Clinical Laboratory Scientist3%

Biologist2%

Lab Management2%

Consultant2%

Marketing/Sales1%

Organization

Academic Institution11%

Biotech Company8%

Hospital6%

Research Institute5%

Clinical Laboratory5%

Pharmaceutical Company4%

Life Science Company3%

Medical School3%

Ambulatory Care3%

Medical Center3%

Consultant3%

Industrial Company2%

Government1%

Distribution/sales1%

Other2%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more